Cervical human papillomavirus genotypes in a high HIV setting: A scoping review of a decade of human papillomavirus epidemiological research in Botswana

Tawe, Leabaneng; Ramatlho, Pleasure; Ketlametswe, Rebecca; Koobotse, Moses O.; Robertson, Erle S.; Grover, Surbhi; Ramogola‐Masire, Doreen; Paganotti, Giacomo Maria

doi:10.3389/fmed.2022.1020760

Cited by 3 publications

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, there is no published work on systematic review and meta-analysis in cervical cancer screening, barriers, and facilitators associated with the disease. Recently, Tawe et al(2022) [24] conducted a scoping review to examine and evaluate HPV genotypes among women of different age groups and HIV status in Botswana (with or without cancer).…”

Section: Introductionmentioning

confidence: 99%

Cervical cancer screening uptake, associated barriers and facilitators: a systematic review and meta-analysis

Omolo

Tladi

Gabaitiri

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Botswana has a high burden of cervical cancer, mainly due to limited screening uptake and a high HIV prevalence. This systematic review and meta-analysis explore the barriers, facilitators, and cervical cancer screening uptake among women in the country. Methods: We identified relevant papers through PubMed/Medline, Scopus, Web of Science, and Google Scholar from 01 January 2013 to 21 November 2022 using predefined inclusion and exclusion criteria. The selection, assessment, and data extraction process was conducted in duplicate by two researchers. We adopted a fixed effects model to pool evidence on the screening uptake. Results: A total of 673 studies were extracted from the four databases from which we remained with nine papers for systematic review, with a total sample size of 3398. The pooled proportion of screening uptake was 0.40 (95% CI; 0.33, 0.47). All selected studies reported on the facilitators while seven studies reported barriers to cervical cancer screening uptake on four levels (individual, institutional, community, and policy levels). Conclusions: The pooled proportion of cervical cancer screening uptake was 40%, which is low, considering the national target to screen 70% of eligible women. The most frequently reported barriers were the low level of knowledge and awareness, misconceptions about screening, and delays in receipt of screening results (in some cases no delivery of results). Reported facilitators included high socio-economic status, having health care insurance, and having a personal health care provider. This work will inform interventions for specific groups of women, which will ultimately reduce the burden of cervical cancer in Botswana.

show abstract

Section: Introductionmentioning

confidence: 99%

Cervical cancer screening uptake, associated barriers and facilitators: a systematic review and meta-analysis

Omolo

Tladi

Gabaitiri

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

HPV- and HIV-associated epigenetic silencing in cervical cancer: Targets for overcoming chemoresistance

Miya,

Ramogola-Masire,

Gaudji

et al. 2024

Strategies for Overcoming Chemotherapy Resistance in Cervical Cancer

View full text Add to dashboard Cite

High-risk human papillomavirus diversity among indigenous women of western Botswana with normal cervical cytology and dysplasia

Rantshabeng,

Tsima,

Ndlovu

et al. 2024

BMC Infect Dis

View full text Add to dashboard Cite

Background Cervical cancer remains a public health problem despite heavy global investment in health systems especially in low-and-middle-income countries (LMIC). Prophylactic vaccines against the most commonly detected human papillomavirus (HPV) types in cervical cancers are available and decisions on the selection of vaccine design depends on the prevalence of high-risk (hr) HPV genotypes for a particular region. In 2015, Botswana adopted the use of a quadrivalent HPV vaccine as a primary prevention strategy. Secondary prevention includes cervical smear screening whose uptake remains notably low among indigenous and marginalized communities despite efforts to improve access. Aim To determine the prevalence of hrHPV genotypes and cervical lesions’ burden in women from the indigenous and marginalized communities of Botswana. Methods This prospective survey enrolled 171 non-HPV vaccinated women aged 21 years and older. Face-to-face interviews, Pap smear screening, hr-HPV and Human Immuno-deficiency virus (HIV) testing were carried out. Conventional Papanicolau smears were analyzed and cervical brushes were preserved for hrHPV testing using the Ampfire Multiplex HR-HPV protocol which detects the following genotypes: HPV 16, 18, 31, 35, 39, 45, 51, 52, 53, 56, 58, 59 and 68. Results In this study, 168/171 (98.6%) of the women consented to HIV testing; 53/171 (31%) were living with HIV and self-reported enrolment on antiretroviral therapy. Among the women examined, 23/171 (13.5%) had cervical dysplasia with most presenting with Atypical Squamous Cells of Undetermined Significance 8/23 (35%), Low-Grade Squamous Intraepithelial Lesions 8/23 (35%), Atypical Squamous Cells-High Grade 4/23 (17%), Atypical Endocervical Cells 2/23 (9%) and Atypical Endocervical Cell favoring neoplasia 1/23(4%). However, no High-Grade Squamous Intraepithelial Lesions (HSIL) or squamous cell carcinoma (SCC) were detected. Overall hrHPV prevalence in this study was at 56/171 (32.7%). The most commonly detected hrHPV genotypes in women with cervical dysplasia were HPV39 (6.25%), HPV51 (14.5%), HPV52 (12.5%) and HPV56 (4%). Notably, HPV 16 and 18 were not found in women with cervical dysplasia. Conclusions Our study provides valuable insights into the prevalence and distribution of hrHPV genotypes in indigenous and marginalized communities in Botswana, and the need for further investigation of their potential role in cervical carcinogenesis in this population. These results may also serve as baseline data to facilitate future evaluation of the HPV vaccine needs.

show abstract

Cervical human papillomavirus genotypes in a high HIV setting: A scoping review of a decade of human papillomavirus epidemiological research in Botswana

Cited by 3 publications

References 46 publications

Cervical cancer screening uptake, associated barriers and facilitators: a systematic review and meta-analysis

Cervical cancer screening uptake, associated barriers and facilitators: a systematic review and meta-analysis

HPV- and HIV-associated epigenetic silencing in cervical cancer: Targets for overcoming chemoresistance

High-risk human papillomavirus diversity among indigenous women of western Botswana with normal cervical cytology and dysplasia

Contact Info

Product

Resources

About